Early Investment Ties Lead to Encore Bet on Protina

Mirae Asset, G&Tech Venture Invest Again in Protina
FIs Join First Fundraising Since Listing
Acquire CBs and CPS Together, Shares Hit Daily Limit

구글에서 선호하는 출처로 추가 관심 있는 뉴스톱 기사를 Google 검색에서 더 쉽게 만나보세요.

글자크기 설정

기사의 본문 내용은 이 글자크기로 변경됩니다.

Mirae Asset Capital and G&Tech Venture Investment, which built strong trust through a successful investment exit, have decided to back protein-analysis platform company Protina once again. Supported by reinvestment from existing financial investors, or FIs, Protina successfully raised a total of $24.8 million (₩36.5 billion), laying the groundwork for a bigger leap through construction of an AI biofoundry and development of its own new drugs.

According to the investment-banking, or IB, industry on Nov. 5, Mirae Asset Capital and G&Tech Venture Investment, a venture-capital affiliate of Kooksoondang, will invest again in Protina after successfully recovering their investment a year ago. Mirae Asset Capital will use a fund jointly formed with Celltrion, while G&Tech Venture Investment will use a fund jointly managed with Kyobo Securities, investing a total of $4.8 million (₩7 billion).

Protina recently held a board meeting and approved a third-party allotment capital increase worth about $5 million (₩7.3 billion) and an issuance of convertible bonds, or CBs, worth $19.9 million (₩29.2 billion). The total amount to be raised is about $24.8 million (₩36.5 billion). The payment date for both is scheduled for Nov. 12.

Of the funds raised, about $17.7 million (₩26 billion) will be used for facilities to build an artificial intelligence, or AI, biofoundry. The company plans initial equipment investment and phased expansion from next year through 2029. The remaining approximately $7.1 million (₩10.5 billion) will be used as operating funds for research and development of its protein-protein interaction, or PPI, analysis platform and development of its own drug candidates, or pipeline.

The capital increase will be conducted by issuing about 150,000 convertible preferred shares, or CPS, at $32.7 (₩48,061) per share. All issued shares will be subject to a one-year mandatory lock-up and can be converted into common shares beginning Nov. 13 next year. The terms also include a refixing provision that adjusts the conversion price if the share price falls. The conversion price can be lowered to $22.9 (₩33,643), or 70% of the initial conversion price. The CBs were issued with a coupon rate of 0% and a yield to maturity of 1%. The CB conversion price and refixing terms are the same as those of the CPS issued through the capital increase.

Investors include Mirae Asset Capital and G&Tech Venture Investment, as well as AJU IB Investment, Kiwoom Investment and Timefolio Capital. Timefolio Capital committed the largest amount at $5.1 million (₩7.5 billion), while Mirae Asset Capital and G&Tech Venture Investment agreed to contribute $2.7 million (₩4 billion) and $2 million (₩3 billion), respectively.

Mirae Asset Capital and G&Tech Venture Investment have previously invested in Protina. They participated in Protina’s $12.9 million (₩19 billion) investment round in 2021. Protina later listed on the KOSDAQ market in July last year at an offer price of $9.5 (₩14,000). Its shares recently hit the daily upper limit intraday and at one point surpassed $37.4 (₩55,000).

The reinvestment comes as Protina expands its business beyond its analysis platform into development of its own new drugs and AI research infrastructure. It is interpreted as existing FIs that have watched the company’s technology and business development placing another bet on its follow-on growth potential.

Celltrion’s decision to reinvest together with Mirae Asset Capital is also drawing attention. Five years ago, Celltrion established ties with Protina through “Mirae Asset Celltrion New Growth Investment Partnership No. 1,” jointly managed with Mirae Asset Capital. It is also participating in this investment through the “Mirae Asset Celltrion Bio Ecosystem Development Fund.”

Protina is a biotechnology company founded in 2015 by CEO Yoon Tae-young, a professor in the Department of Biological Sciences at Seoul National University. It independently developed “SPID,” a platform that measures and analyzes protein-protein interactions. Recently, it has been expanding its biofoundry business, which experimentally validates antibody candidates designed by AI. It signed a memorandum of understanding, or MOU, with U.S.-based Twist Bioscience and plans to increase its analysis capacity from about 40,000 cases per month to 1 million per month by 2028.

(Reference: USD equivalent, KRW/USD ≈ 1,471. Applied as ₩1,471 = $1.00 for convenience.)

이 기사가 마음에 드셨나요?

댓글 (0)

아직 댓글이 없습니다. 첫 댓글을 작성해보세요!

당신이 좋아할 만한 기사